Skip to main content

Eurobio Scientific expands into Switzerland, Germany, Austria and Benelux by acquiring the diagnostic company TECOmedical AG

Written by Customer Service on . Posted in Mergers And Acquisitions.

Eurobio Scientific expands into Switzerland, Germany, Austria and Benelux by acquiring the diagnostic company TECOmedical AGParis, July 15, 2020 –7:30 amEurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), a leading French group in the field of specialty in vitro medical diagnostics, announces the acquisition of 100% of the share capital of TECOmedical AG (“TECO”), parent company of a Swiss group specializing in the development and distribution of in vitro diagnostic tests in Europe, with operations in Switzerland, Germany, Austria and Benelux. The acquisition, which financial terms are not disclosed, was paid in cash.A strong reputation in specialty tests for medical diagnosticsFounded in 1984, TECO is based in Sissach, Switzerland. The company offers a range of specialty biomarker assays under exclusive distribution contracts, as well as proprietary products for human and veterinary diagnostics, eco toxicology and metabolic syndromes. Its 2019 consolidated revenue was €7.2 million.
The TECO group markets its products in Europe through TECOmedical AG Switzerland, TECOmedical GmbH (Germany and Austria), TECOmedical Benelux BV (Netherland, Belgium and Luxemburg), with a central European warehouse located near Frankfurt.
TECO develops and manufactures its proprietary products through TECOdevelopment GmbH, located in Rheinbach, Germany.
Eurobio-Scientific is currently marketing specific products from TECO in France and the UK.An acquisition in line with the Group’s European development strategyThis acquisition fits perfectly with Eurobio Scientific’s European development strategy. With an already long-standing commercial relationship with TECO, it also enables a closer proximity to the largest European markets for diagnostic and research products, and opens opportunities for expanding the Eurobio Scientific group in German speaking countries and Benelux, its presence being currently limited to France and French speaking areas of Belgium, Switzerland and Luxemburg.Jean-Michel Carle, President and CEO of Eurobio Scientific, declares: “we are delighted to welcome the TECOmedical team within our Group. This acquisition brings us a wide range of products that is highly complementary to our own, as well as an opening on the German-speaking markets in Europe. The long-standing relationship between our two groups will enable us to rapidly activate the commercial and technological synergies resulting from this operation.”Denis Fortier, joint CEO of Eurobio adds: “The way we handled the COVID-19 crisis has strengthened our financial position and shown our capacity to absorb growth. Acquiring TECOmedical is another way of accelerating our development, with a long-term growth potential built on geographic and product complementarities.”Marieluise Wippermann, CEO of TECOmedical Group, “Eurobio Scientific is the best match for TECOmedical as we share a common business model, built on a mix of exclusive distribution contracts and proprietary products issued from our own R&D capacities. We join forces at the right moment, when the health systems all over Europe rely more and more on diagnostic.”About TECOmedical
The Swiss-based TECOmedical Group with subsidiaries in Germany and Benelux, is a leading provider of in-vitro specialty test systems in the areas of medical and veterinary diagnostic, biosafety and environmental testing.
In addition, it develops and evaluates new test systems in collaboration with opinion leaders or as service to pharma, CRO and research organizations.Next financial meeting
Eurobio Scientific 2020 first-half revenues: July 21, 2020  Attachment200715_EUROBIO_TECO_ACQUISITION_EN

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.